July 21, 2019


Cancer Immunotherapy-Hope Medical Group

We provide Cancer Immunology that use your own cells or umbilical cord cells to both kill many cancers and boost the immune system.

Our Guangzhou - DC-CIK Cancer Treatment hospital has its own laboratory for cell separation and cell cultures. Our laboratory is directed by Dr Wong, who is formerly America’s leading stem cell & DC-CIK cell researcher.

Patients choose China to undergo Cancer Stem Cell Treatment with us regularly.
In most cases it is more effective than chemotherapy, radiation or surgery and without the side effects.

Patients that we have treated have had a 85% survival rate after 5 years of having the treatment. 

CIK or CIK-DC Immunotherapy Print
"Instead of using surgery, chemotherapy, or radiotherapy, researchers from the National Institutes of Health are finding inspiring success in a new approach for fighting cancer, using the immune system to attack the tumors the way it would be a cold or flu."   - CNN.com (August 2006) 

New approach to break cancer's defences
"The great advantage of immunotherapy is that it is very safe to use, with none of the toxic side effects of normal chemo or radiotherapy," the specialist said.

"Because of this, immunotherapies can be administered generally without having to target the cancer specifically, making them much easier to deliver."
Professor Ian Frazer - Cited: April 9, 2008 Sydney Morning Herald
You can review published medical papers here.
Treatment Method :

Number of Injection - 9 units of high density second generation DC+CIK cell (DC-CIK)

Type of Injection - Intravenous (IV) Injection x 9 of high density DC+CIK cell (DC-CIK) (We may double the dosing and give 2 rounds each time.)

Adjuvant Therapy :

Chinese traditional medicine to recuperate, physical therapy, any other therapies needed are included.

Treatment Period :

9 days

The payment includes:

DC+CIK cell implantation :
Physiotherapy and occupational therapy sessions, from Monday to Friday,
Traditional Chinese medicine
Accommodation for the patient AND for 1 or 2 accompanying family members.
General medical services ; Doctor's visits and examinations, laboratory tests, etc

Side effects:
None in over 20,000 cases treated worldwide.

Foreign patient services:

Our international department team helps our foreign patients handle all the communication aspects of getting medical treatment in a foreign country. Staff is ready to help with everything from communicating with the medical team, nurses, and caregivers to daily needs like shopping, going to the bank, or making visa arrangements. We also provide transportation from the airport to the hospital upon arrival and make all necessary arrangements for transportation to the airport upon completion of the treatment.

About Immunotherapy 

Treatment to stimulate or restore the body's natural abilities of the immune (defense) system to fight infection and disease and to protect the body from some of the side effects of treatment.

What are CIK cells?

Cytokine-induced killer (CIK) cells are immune cells that can seek and kill tumor cells. CIK cells were discovered in 1991 by Lanier and Schmidt-Wolf*. Further in-depth research was later conducted at the Stanford University Medical Center. 

CIK has proved in medical practice to be the most efficiently adopted immunotherapy.  It shows good efficacies in treating malignant tumors in leukemia, melanoma, malignant lymphoma, renal cell carcinoma, metastatic renal carcinoma, lung cancer, liver cancer, breast cancer, ovarian cancer, colon cancer, and gastric cancer.

CIK cells are generated in vitro from single peripheral blood mononuclear cell (PBMC) by addition of interferon-gamma (IFN-γ), interleukin (IL)-2, IL-1 and antibody against CD3 (anti-CD3 mAb), with surface markers for both T-cell (TCR-α/β, CD3) and NK cell (CD56). Compared to the lymphokine-activated killer (LAK) and tumor-infiltrating lymphocytes (TIL) used in the former adoptive immunotherapy, CIK has an enhanced proliferation and ability to kill tumors, with low toxicity and few side effects. CIK biotherapy can kill cancerous cells directly, regulate and strengthen the immunity, and restore to the maximum extent the normal cell growth regulator, without any damage to immune system and function. It provides a thorough new method to treat tumors. 

How do CIK cells kill tumor cells?

a. CIK cells are non-major histocompatibility complex (MHC). Thus CIK cells are capable of recognizing and killing different types of tumor cells though different mechanisms. The cytolytic activity of CIK cells makes themselves fuse with tumor cells and release cytoplasmic granules that dissolve the tumor.

b. CIK cells, after induced and transfected by dendritic cells, have a strengthened ability to proliferate and kill tumors, and a greater precision to target and kill tumor cells by inducing apoptosis.

c. CIK cells produce IL-2, IL-6, IFN-r and other anti-tumor cytokines

d. CIK cells injected back into humans can reactivate the immune system and enhance the immune functions.

What is DC-CIK immunotherapy?

DC-CIK biotherapy uses CIK cells induced and transfected by dendritic cells (DC). Dendritic cells are the most powerful type of antigen-presenting cell. DC can present the tumor antigen to DIK cells and double the ability to recognize cancerous cells.

Compared to CIK biotherapy, DC-CIK biotherapy has a greater precision to seek and kill tumor cells and helps to increase the sensitivity of cancerous cells to chemotherapy.

What are the indications of CIK immunotherapy?

CIK is not restricted by histocompatibility of tumors and kills all types of tumors. Also, it has a better therapeutic effect on cancer with high expression of antigens. CIK biotherapy has an impressive efficacy on liver cancer, lung cancer, colon cancer, breast cancer, and ovarian cancer, as well as on malignant tumors such as myeloid leukemia, melanoma, renal cell carcinoma, metastatic renal cell carcinoma, malignant lymphoma (except T-cell lymphoma), and non-Hodgkin’s lymphoma.

This treatment can be applied to cancer patients in any stage, and it has good long-term effects for both early stage patients and advanced stage ones. CIK cells eliminate small lesions not available for surgery and tiny cancerous cells scattered in the body to delay or prevent the metastasis or recurrence of tumor. It will have a better efficacy when combined with surgical resection, intervention, radiofrequency therapy, or cryoablation.

What are the contraindications of CIK immunotherapy?

a. Pregnancy and lactation

b. Uncontrolled severe infection

c. Severe allergic constitution

d. T-cell lymphoma

e. Epilepsy


What are the features of CIK immunotherapy in clinical applications?

CIK biotherapy is currently the first choice of adopted immunotherapies. It has the following features:

a.  CIK cells can recognize the tumor cells and are not toxic to normal cells.

b. CIK cells have a wide spectrum against tumors and are also sensitive to multi-drug resistant tumor cells.

c.  CIK biotherapy helps to enhance immunity with a specific antiviral ability.

d. CIK cells are very safe to use since they are activated autologous cells.

e.  CIK cells effectively remove the remnant cancerous cells or small lesions, and prevent tumor recurrence.

f.   CIK Biotherapy, when combined with radiotherapy or chemotherapy, enhances the efficacy and reduces the toxicity, side effects, and infections.

g.  For advanced stage patients who have no chance for surgery and for patients who suffer recurrence or metastasis, large doses of CIK can quickly relieve the symptoms of advanced cancer patients, improve the quality of life (increased appetite, improved sleep and enhanced physique), and prolong the survival time. In some cases, the tumors can shrink or even disappear, and long-term survival is achieved.

h. Since CIK can regulate the immunity, during the treatment of the tumor, patients may notice glossy skin, faded speckles, or grey hairs turning black again. 

What are the adverse reactions of CIK immunotherapy?

CIK cells are activated autologous cells. Therefore, CIK biotherapy is very safe. No serious adverse reactions are observed. In a small number of cases, a rise of body temperature (37.2℃-40℃) was observed 2-10 hours after reinfusion. Generally, the temperature will drop back to normal in 2-10 hours, and only a few patients need antipyretics to alleviate the fever.

Dentritic Cell Immunotherapy

How are the CIK immunotherapeutic cycles organized?

Usually one CIK biotherapeutic cycle lasts 14-30 days. Mononuclear cells are first collected from peripheral blood (PBMC). Cells are cultured, induced, activated, and compounded in GMP-standardized laboratory for 10 days. Reinfusion can be applied everyday starting after the 10th day of cell culture according to the requirements.

The number of treatment cycles and the interval depends on the following aspects:

a. Level of immunity (age, physical strength, stress, monophagia, nutrition, and other disease)

b. Clinical stage and lesions (tumor size and metastasis or not. A lump of 1 cm3 approximately has 1 billion cancerous cells.)

c. Living habits (food, sleep, work, sports, etc.)

d. Treatments that have been or will be taken (surgery, chemotherapy, radiotherapy, etc.)

f.  Evaluation on stage (blood tests and imaging reports)

e. Consumption capability of the patients

f.  Expectation and understanding on curative effect to achieve by the patient and the family members.

Summary of treatment plan based on long-term clinical practices:

How CIK cells are divided?

CIK cells can be divided by their sources:

a. Allogeneic CIK

Peripheral blood mononuclear cells are collected from healthy blood type O donors, and then cultured, transfected and cloned in GMP-standardized laboratory. Usually, reinfusion will be available a week after appointment.

Application group:

Patients of all stages within five years, especially for patients in advanced stage or with high blood lipid. Allogeneic CIK has adequate sources of cells and can be reinfused repeatedly with large dosage. Therefore, it can be used to rescue advanced cancer patients.

How many times are the CIK cells reinfused?

Usually, reinfusions will be applied 1-6 times a week at the dosage of >1×109. Reinfusion lasts for 2 hours. It has no toxicity or side effects, and causes no pain.

 b. Cord blood CIK

Mononuclear cells are collected from healthy cord blood, and then are cultured, transfected and cloned in GMP-standardized laboratory. Usually, reinfusion will be available a week after appointment.

Application group:

Patients of all stages within five years, especially for patients in advanced stage or with high blood lipid. Allogeneic CIK has an adequate sources of cells and can be reinfused repeatedly with large dosage. Therefore, it can be used to rescue advanced cancer patients.

How many times are the CIK cells reinfused?

Usually, reinfusions will be applied 1-6 times a week at the dosage of >1×109. Reinfusion lasts for 2 hours. It has no toxicity or side effects, and causes no pain.

c. Autologous CIK

Peripheral blood mononuclear cells are collected from the patient, and then are cultured, transfected, and cloned in GMP-standardized laboratory. Times of reinfusion depend on number and quality of cells collected.

Application group:

Patients in stable condition that are have confirmed cancer for 3-5 years, or sub-healthy patients.

How many times are the CIK cells reinfused?

Usually, reinfusions will be applied 1-6 times a week at the dosage of >1×109. Reinfusion lasts for 2 hours. It has no toxicity, side effects, or pain.

Clinical summary of CIK immunotherapy

a. How does CIK strengthen the effect of surgery?

Surgery can remove the local lesions quickly, but it does nothing to metastatic cancerous cell and small lesions. Subsequently, the immunity of patients decreases sharply. Immediate application of CIK immunotherapy after surgery could rapidly remove scattered small lesions and cancerous cells, prevent recurrence and metastasis effectively, and increase the immunity.

b. How does CIK immunotherapy enhance the efficacy of radiotherapy?

Radiotherapy can only destroy part of cancerous cells. It cannot kill the cancerous cells in blood, nor can it destroy small metastatic or hidden lesions, which may lead to recurrence. In addition, when radiation is killing cancerous cells, it kills a large number of leukocytes as well, which is a great harm to normal tissue function. However, CIK cells have an impressive ability to distinguish and destroy cancerous cells, with no side effects to normal cells. CIK cells can track and destroy cancerous calls in blood as well as small metastatic or hidden lesions in the body to inhibite cancer recurrence. Therefore, CIK biotherapy can be applied before, during, and after radiotherapy.

c. How does CIK immunotherapy enhance the efficacy of chemotherapy?

Chemotherapy has a good efficacy to kill cancerous cells in blood, but the chemicals used in chemotherapy have poor stability and penetrating ability inside the body. In addition, certain malignant tumors develop resistance to the chemicals. Thus, chemotherapy is nearly of no use to control metastatic or hidden lesions. In the process of chemotherapy, the body's blood immune system is significantly disrupted, causing a series of side effects, such as hair loss, vomiting, loss of appetite, rash, and so on. To maximize effectiveness of chemotherapy while minimizing the side effects, immune system function must be improved. Addition of CIK cells to the chemotherapy can inhibit the resistance to the chemotherapy chemicals, lower the infection rates in chemotherapy, and increase the sensitivity of cancerous cells to chemotherapy. Therefore, CIK should be applied throughout the chemotherapy.

d. Comparison of CIK immunotherapy to the other biotherapies.

i) Cytokines: Interferon, Thymosin and Interleukin, as representatives. They function by stimulating the immune cells to proliferate and activate, and they are relatively cheap and commonly used. Cytokines are mainly used for supporting immunotherapy.

ii) Cells: LAK and CIK, as representatives, featured in anti-tumor whole cells. CIK cells were first introduced later than LAK cells. CIK cells have a much higher ability of proliferation and tumor killing activity than the LAK. The efficacy of CIK is 73 times of LAK's. CIK cells are independent of MHC restriction. Unlike LAK cells, CIK cells need no IL-2 to kill tumor, and thus to avoid the side effects from IL-2. Concerned of cost, CIK is dozens of times more effective than CIK. So CIK is the safest, most advanced, and most effective method of biotherapies.

Generally speaking, CIK biotherapy is the most promising biotherapy, due to its broad spectrum of merits: killing tumors, rapid proliferations, no serious adverse reactions, mature and safe technology, high efficiency and acceptable price.

DC-CIK biological cells provide treatment for Most Common Cancers :

  • Lung Cancer
  • Colorectum Cancer
  • Prostate Cancer
  • Liver Cancer
  • Nasopharynx Cancer
  • Stomach Cancer
  • Non-Hodgkin's Lymphoma Cancer
  • Oesophagus Cancer
  • Non-Melanoma Skin Cancer
  • Kidney and Other Urinary Organs
  • Breast Cancer
  • Corpus Uteri Cancer
  • Thyroid Cancer
  • Ovary Cancer
  • Cervical Cancer

For more information on stem cell immunotherapy for cancer, please complete a medical form here or visit http://hopestemcell.com/This email address is being protected from spambots. You need JavaScript enabled to view it." title="Contact Us">

 Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling.

2011 Jan 18;19(1):125-37.


Sonoshita M, Aoki M, Fuwa H, Aoki K, Hosogi H, Sakai Y, Hashida H, Takabayashi A, Sasaki M, Robine S, Itoh K, Yoshioka K, Kakizaki F, Kitamura T, Oshima M, Taketo MM.


Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.


Metastasis is responsible for most cancer deaths. Here, we show that Aes (or Grg5) gene functions as an endogenous metastasis suppressor. Expression of Aes was decreased in liver metastases compared with primary colon tumors in both mice and humans. Aes inhibited Notch signaling by converting active Rbpj transcription complexes into repression complexes on insoluble nuclear matrix. In tumor cells, Notch signaling was triggered by ligands on adjoining blood vessels, and stimulated transendothelial migration.


Genetic depletion of Aes in Apc(Δ716) intestinal polyposis mice caused marked tumor invasion and intravasation that were suppressed by Notch signaling inhibition.


These results suggest that inhibition of Notch signaling can be a promising strategy for prevention and treatment of colon cancer metastasis.

Copyright © 2011 Elsevier Inc. All rights reserved.

PMID: 21251616 [PubMed - indexed for MEDLINE]


Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots.

Korkaya H, Liu S, Wicha MS.

Authors' Affiliation: Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan.


2011 Oct 1;17(19):6125-9. Epub 2011 Jun 17.


There is substantial evidence that many human cancers are driven by a subpopulation of cells that display stem cell properties. These cancer stem cells (CSC) may also contribute to metastasis and treatment resistance. Furthermore, just as normal stem cells are regulated by their microenvironment, or niche, CSCs interact with and in turn are regulated by cells in the tumor microenvironment.


These interactions involve inflammatory cytokines, such as interleukin (IL)-1, IL-6, and IL-8, which in turn activate Stat3/NF-κB pathways in both tumor and stromal cells. Activation of these pathways stimulates further cytokine production, generating positive feedback loops that in turn drive CSC self-renewal. These cytokine loops and the pathways they regulate resemble those activated during chronic inflammation and wound healing, and may contribute to the known link between inflammation and cancer. Inhibitors of these cytokines and their receptors have been developed as anti-inflammatory agents.


By blocking signals from the tumor microenvironment, these agents have the potential to target CSCs. Future clinical trials using these compounds will be needed to determine whether targeting the CSC population has clinical benefit. Clin Cancer Res; 17(19); 6125-9. ©2011 AACR.

PMID: 21685479 [PubMed - in process]


Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma.

Lu XC, Yang B, Yu RL, Chi XH, Tuo S, Tuo CW, Zhu HL, Wang Y, Jiang CG, Fu XB, Yang Y, Liu Y, Yao SQ, Dai HR, Cai LL, Li BJ, Han WD.


2011 Sep 13. [Epub ahead of print]


Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, 100853, China,

To evaluate the effectiveness and safety of autologous cytokine-induced killer (CIK) cells in elderly patients with diffuse large B-cell lymphoma. Peripheral blood mononuclear cells (PBMC) were isolated from nine elderly patients with diffuse large B-cell lymphoma. PBMCs were augmented by priming with interferon gamma (IFN-γ) followed by IL-2 and monoclonal antibody (mAb) against CD3. Autologous CIK cells (range 5 × 10(9)-1 × 10(10)) were then infused back to individual patients; infusion was repeated every 4 weeks for 32 weeks (eight cycles). Patients were assessed for changes in lymphocyte subgroup, tumor-related biological parameters, imaging characteristics, the condition of remission, quality of life (QOL), and survival.


Prior to CIK infusion, two patients were in complete remission and seven patients were in partial remission.


After autologous CIK cell transfusions, the proportion of CD3+, CD3+CD8+, and CD3+CD56+ cells were significantly increased compared with baseline (P < 0.05); whereas serum levels of β2-microglobulin and LDH were significantly decreased (P < 0.05). The lymphoma symptoms were reduced and QOL was improved (P < 0.05) in all patients. All patients achieved complete remission at study endpoint.


No adverse reactions were reported. Autologous CIK cell immunotherapy is safe and efficacious for the treatment of elderly patients with diffuse large B-cell lymphoma.

PMID: 21913005 [PubMed - as supplied by publisher]

The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.

Rettinger E, Kuçi S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M, Klingebiel T, Fulda S, Bader P.

2011 Oct 6. [Epub ahead of print]

University Children's Hospital of Frankfurt/Main and Department of Pediatric Hematology, Oncology and Hemostaseology, Goethe-University Frankfurt/Main , Frankfurt/Main , Germany.

Abstract Background aims. Cytokine-induced killer (CIK) cells may serve as an alternative approach to adoptive donor lymphocyte infusions (DLI) for patients with acute leukemia relapsing after haplo-identical hematopoietic stem cell transplantation (HSCT).


We investigated the feasibility of enhancing CIK cell-mediated cytotoxicity by interleukin (IL)-15 against acute myeloid and lymphoblastic leukemia/lymphoma cells. Methods. CIK cells were activated using IL-2 (CIK(IL-2)) or IL-15 (CIK(IL-15)) and phenotypically analyzed by fluorescence-activated cell sorting (FACS). Cytotoxic potential was measured by europium release assay. Results. CIK(IL-2) cells showed potent cytotoxicity against the T-lymphoma cell line H9, T-cell acute lymphoblastic leukemia (T-ALL) cell line MOLT-4 and subtype M4 acute myeloid leukemia (AML) cell line THP-1, but low cytotoxicity against the precursor B (pB)-cell ALL cell line Tanoue. IL-15 stimulation resulted in a significant enhancement of CIK cell-mediated cytotoxicity against acute lymphoblastic leukemia/lymphoma cell lines as well as against primary acute myeloid and defined lymphoblastic leukemia cells. However, the alloreactive potential of CIK(IL-15) cells remained low. Further analysis of CIK(IL-15) cells demonstrated that the NKG2D receptor is apparently involved in the recognition of target cells whereas killer-cell immunoglobulin-like receptor (KIR)-HLA mismatches contributed to a lesser extent to the CIK(IL-15) cell-mediated cytotoxicity.


In this context, CD3 (+) CD8 (+) CD25 (+) CD56(-) CIK(IL-15) cell subpopulations were more effective in the lysis of AML cells, in contrast with CD56 (+) CIK(IL-15) cells, which showed the highest cytotoxic potential against ALL cells.

Conclusions. This study provides the first evidence that CIK(IL-15) cells may offer a therapeutic option for patients with refractory or relapsed leukemia following haplo-identical HSCT.

PMID: 21973023 [PubMed - as supplied by publisher]




International patients contact:


This email address is being protected from spambots. You need JavaScript enabled to view it.


Hospital Treatments